Cizzle Biotech list in London to accelerate their research for early detection of lung cancers

Cizzle Biotech PLC’s (LON:CIZ) executive chairman Allan Syms joins Proactive London on their first day of dealings on the standard segment of the main market of the London Stock Exchange.

Syms talks through their operations, they are developing a blood test for the early detection of lung cancers, said ahead of the listing it raised £2.2mln through the placing of 22mln new shares at a price of 10p each.